The role of a transcriptional factor GATA3 in maxillofacial development
| Project/Area Number |
16H07149
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Morphological basic dentistry
|
|---|
| Research Institution | Tohoku University (2017)
Tohoku Medical and Pharmaceutical University (2016) |
|---|
Principal Investigator |
Otsuki Akihito 東北大学, 東北メディカル・メガバンク機構, 助教 (30778022)
|
|---|
| Project Period (FY) |
2016-08-26 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | GATA3 / 転写制御 / 発生・分化 / ゲノム |
|---|
| Outline of Final Research Achievements |
GATA3 is a zinc finger transcription factor that plays a crucial role in embryonic tissue development. Here, we analyzed the expression profile of GATA3 in pharyngeal arch, and demonstrate that Gata3 hypomorphic mutant mice exhibit neonatal lethality associated with oral and renal malformation. Moreover, we found that the 662-kb Gata3 yeast artificial chromosome (YAC) recapitulated Gata3 expression in pharyngeal arch and renal tubules. A transgenic rescue mouse line generated by breeding the hypomorphic mutant with a transgenic mouse line bearing the YAC construct survived to adulthood. These result shows a crucial role for GATA3 in maxillofacial development.
|
Report
(3 results)
Research Products
(9 results)
-
-
-
[Journal Article] Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation.2017
Author(s)
Tsuchida K, Tsujita T, Hayashi M, Ojima A, Keleku-Lukwete N, Katsuoka F, Otsuki A, Kikuchi H, Oshima Y, Suzuki M, Yamamoto M.
-
Journal Title
Free Radic Biol Med
Volume: 103
Pages: 236-247
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-
-
